Clinical Trials Browser

Phase 2 × INDUSTRY × Ras-mutated Metastatic Colorectal Cancer × Clear all

NCT07446322 2026-03-04

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Ras-mutated Metastatic Colorectal Cancer